NCT04944030 Clinico-biological Data Collection Study of Metastatic Lung Cancer
| NCT ID | NCT04944030 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Cancerologie de l'Ouest |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-04-24 |
| Primary Completion | 2031-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2023-04-24 with a primary completion date of 2031-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
RATIONALE : Currently, the mechanisms associated with the response or resistance to treatment are poorly understood and are multifactorial. These mechanisms involve clinical and biological factors associated with the host and the tumor and possibly the patient's psycho-social environment. PURPOSE : This trial will assess the use of a prospective database dedicated to patients with breast cancers that contains clinical data as well as epidemiological, psychological, emotional, social, imaging, biological and biopathological data. These data will allow a creation of new modelling algorithms in order to predict response and resistance to treatment.
Eligibility Criteria
Inclusion Criteria: * Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening biopsy, blood sample and questionnaires * 18 years old at time of written consent * Patient with histologically confirmed lung cancer * Lung cancer metastatic disease or locally advanced not eligible for local curative treatment intent * Performance status ≤ 2 (according to WHO criteria) * Indication of any systemic therapeutic strategy can be performed alongside this current cohort in accordance with national and / or international recommendations. * Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. * Patient must be affiliated to a Social Health Insurance Exclusion Criteria: * Other malignancy treated within the last 3 years (except non-melanoma skin cancer or in situ carcinoma of the cervix) * Other neuroendocrine t
Frequently Asked Questions
Who can join the NCT04944030 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04944030 currently recruiting?
Yes, NCT04944030 is actively recruiting participants. Visit ClinicalTrials.gov or contact Institut Cancerologie de l'Ouest to inquire about joining.
Where is the NCT04944030 trial being conducted?
This trial is being conducted at Angers, France, Saint-Herblain, France.
Who is sponsoring the NCT04944030 clinical trial?
NCT04944030 is sponsored by Institut Cancerologie de l'Ouest. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.